Ovarian Epithelial Cancer Clinical Trial
Official title:
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: A Randomized Clinical Trial for Early Versus Delayed Interval Cytoreductive Surgery
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis. When complete surgery with no macroscopic visible disease is not feasible due to both the spread of the disease and the patient's general condition, neoadjuvant chemotherapy (NACT) of 3 cycles followed by interval cytoreductive surgery (ICS) or final cytoreductive surgery (FCS) after 6 cycles of NACT followed or not by adjuvant chemotherapy can be offered, with similar overall survival. In our centre, due to logistics, disease, or patient factors, many patients may receive more than 3 cycles of NACT before ICS. Therefore, this randomized controlled trial aims to evaluate the survival benefit of different timings of ICS after 3 or 6 cycles of NACT in patients not eligible for upfront cytoreductive surgery (UCS).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02096783 -
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
|
N/A | |
Active, not recruiting |
NCT01456065 -
Safety of Active Immunotherapy in Subjects With Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03220932 -
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05937620 -
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
|
N/A | |
Completed |
NCT02107937 -
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT02039388 -
Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma
|
N/A | |
Completed |
NCT02107950 -
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT01806350 -
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors
|
N/A | |
Recruiting |
NCT03349463 -
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
|
Phase 4 | |
Completed |
NCT04823871 -
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
|
N/A | |
Completed |
NCT02518256 -
Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity
|
N/A | |
Active, not recruiting |
NCT03078400 -
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
|
Phase 1 | |
Completed |
NCT02489903 -
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
|
Phase 2 | |
Not yet recruiting |
NCT02435186 -
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
|
Phase 2 | |
Recruiting |
NCT04029909 -
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
Suspended |
NCT02742428 -
Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT02981901 -
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
|
||
Completed |
NCT02062697 -
Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.
|
N/A |